Indication
Hematologic malignancy
A hematologic malignancy is a broad clinical category encompassing cancers that originate in blood-forming tissues, such as the bone marrow, or in cells of the immune and lymphatic systems. Read more about Hematologic malignancy
5 drugs 1 manufacturers
Drugs that treat it
Common Hematologic malignancy therapies.
TREGZI HSPC AND TREG COMPONENT (allogeneic regulatory T cell immunother-vldq,HSPCs and Tregs)
TREGZI HSPC COMPONENT (allo reg T cell immuno-vldq, HSPCs (CD34+), step 1 of 3)
TREGZI TCON COMPONENT (allo reg T cell immuno-vldq, Tcons (CD3+), step 3 of 3)
TREGZI TREG COMPONENT (allo reg Tcell-vldq, Tregs (CD4+CD25+CD127-), step 2 of 3)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonA hematologic malignancy is a broad clinical category encompassing cancers that originate in blood-forming tissues, such as the bone marrow, or in cells of the immune and lymphatic systems.
These neoplasms affect pediatric and adult populations and primarily include leukemias, lymphomas, and plasma cell neoplasms such as multiple myeloma, as well as related conditions like myelodysplastic syndromes and myeloproliferative neoplasms.
Pathophysiologically, they are characterized by the clonal expansion, impaired differentiation, and uncontrolled proliferation of abnormal hematopoietic or lymphoid precursors.
Clinically, this marrow infiltration and tissue disruption often result in cytopenias, impaired immune function, generalized lymphadenopathy, organomegaly, and systemic symptoms.
- cancer.gov
A hematologic malignancy is a broad clinical category encompassing cancers that originate in blood-forming tissues, such as the bone marrow, or in cells of the immune and lymphatic systems
- nih.gov
A hematologic malignancy is a broad clinical category encompassing cancers that originate in blood-forming tissues, such as the bone marrow, or in cells of the immune and lymphatic systems These neoplasms affect pediatric and adult populations and primarily include leukemias, lymphomas, and plasma cell neoplasms such as multiple myeloma, as well as related conditions like myelodysplastic syndromes and myeloproliferative neoplasms
- nih.gov
These neoplasms affect pediatric and adult populations and primarily include leukemias, lymphomas, and plasma cell neoplasms such as multiple myeloma, as well as related conditions like myelodysplastic syndromes and myeloproliferative neoplasms
- beckman.com
Pathophysiologically, they are characterized by the clonal expansion, impaired differentiation, and uncontrolled proliferation of abnormal hematopoietic or lymphoid precursors Clinically, this marrow infiltration and tissue disruption often result in cytopenias, impaired immune function, generalized lymphadenopathy, organomegaly, and systemic symptoms
- inbirg.com
Pathophysiologically, they are characterized by the clonal expansion, impaired differentiation, and uncontrolled proliferation of abnormal hematopoietic or lymphoid precursors
- medlineplus.gov
Clinically, this marrow infiltration and tissue disruption often result in cytopenias, impaired immune function, generalized lymphadenopathy, organomegaly, and systemic symptoms
Personalize your experience
Follow Hematologic malignancy and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.